Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 20/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 20/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 19/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 19/20 | 1.00 |
| ▸ | CHRNG | P07510 | 18/20 | 1.00 |
| ▸ | CHRND | Q07001 | 18/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radafaxine SCHEMBL30486031 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL29751668 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL29465705 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3453827 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL2599138 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL13014841 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL48964 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3453734 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL14521595 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL5478077 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | claimed |
| US-20080281096-A1 | Resolution Process For Preparing (+)-2S,3S)-2-(3-Chlorophenyl)-3,3,3-Trimethyl-2-Morpholinol | HARRIS MICHAEL ANTHONY | 2008-11-13 | — | — | US | claimed |
| US-20070123533-A1 | New process for preparing an optically pure 2-morpholinol derivative | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | US | claimed |
| US-20070093486-A1 | Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof | SMITH KLINE BEECHAM CORPORATION ,CORPORATION | 2007-04-26 | — | — | US | claimed |
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | Smith Kline Beecham Corporation D/b/a Glaxo Smith Kline (US) | 2007-02-08 | — | — | US | claimed |
| US-20020147196-A1 | Composition and method for treating neuropathic pain | GLAXO GROUP LIMITED (GB) | 2002-10-10 | — | — | US | claimed |
| US-20240366513-A1 | Methods For Administering Weight Loss Medications | NALPROPION PHARMACEUTICALS LLC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12048769-B2 | Methods for administering weight loss medications | NALPROPION PHARMACEUTICALS LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230301922-A1 | Layered Pharmaceutical Formulations | NALPROPION PHARMACEUTICALS LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20200352863-A1 | Methods For Administering Weight Loss Medications | Naipropion Pharmaceuticals LLC (US) | 2020-11-12 | — | — | US | disclosed |
| US-20190282503-A1 | Methods For Administering Weight Loss Medications | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2019-09-19 | — | — | US | disclosed |
| US-20190262318-A1 | Method for Treating Obesity | NALPROPION PHARMACEUTICALS LLC | 2019-08-29 | — | — | US | disclosed |
| US-10307376-B2 | Methods for administering weight loss medications | NALPROPION PHARMACEUTICALS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20030027827-A1 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION | 2003-02-06 | — | — | US | disclosed |
| US-20020147196-A1 | Composition and method for treating neuropathic pain | GLAXO GROUP LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| US-6391875-B2 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-20020019396-A1 | Pharmaceutically active morpholinol | MORGAN PHILLIP FREDERICK (US) | 2002-02-14 | — | — | US | disclosed |
| US-6274579-B1 | ANTIDEPRESSANTS, ANALGESICS; SEXUAL DISORDERS, ATTENTION DEFICIT DISORDER; DRUG ADDICTION; PARKINSON*S AND ALZHEIMER*S DISEASE; HEADACHES, OBESITY | GLAXO WELLCOME INC. | 2001-08-14 | — | — | US | disclosed |
| EP-1047428-A1 | PHARMACEUTICALLY ACTIVE MORPHOLINOL | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999037305-A1 | PHARMACEUTICALLY ACTIVE MORPHOLINOL | GLAXO GROUP LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281096-A1 | Resolution Process For Preparing (+)-2S,3S)-2-(3-Chlorophenyl)-3,3,3-Trimethyl-2-Morpholinol | TPMT, MTAP, METTL3 | CHRNB2 1449/4885SLC6A2 327/4885CHRNB4 2436/4885 |
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | METTL3, TPMT, MTAP | CHRNB2 2457/4885SLC6A2 236/4885CHRNB4 2932/4885 |
| US-20030027827-A1 | Pharmaceutically active morpholinol | ACHE, COMT, MGLL | CHRNB2 87/4885SLC6A2 80/4885CHRNB4 57/4885 |
| US-20020019396-A1 | Pharmaceutically active morpholinol | ACHE, COMT, OPRL1 | CHRNB2 74/4885SLC6A2 67/4885CHRNB4 54/4885 |
| US-20070093486-A1 | Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof | MTAP, RNGTT, SPR | CHRNB2 1437/4885SLC6A2 1202/4885CHRNB4 2109/4885 |
| US-20190262318-A1 | Method for Treating Obesity | SLC6A2, COMT, GAP43 | CHRNB2 183/4885SLC6A2 1/4885CHRNB4 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.